Fersinsa Gb, S.A. de C.V. DMF, CEP, Written Confirmations, FDF, Prices, Patents, Patents & Exclusivities, Dossier, Manufacturer, Licensing, Distributer, Suppliers, News

SPI Pharma has been solving formulation challenges using superior functional materials.

Virtual Booth

Contact Supplier

Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

VISIT THE VIRTUAL BOOTH
Review portfolio & marketing content
CONTACT DETAILS
Google Map, LinkedIn, Emails...

DIGITAL CONTENT

Interview #SpeakPharma, Vlog #PharmaReel, Data Compilation #PharmaFlow, 102 News #PharmaBuzz

media
Interview #SpeakPharma
Vlog #PharmaReel
Data Compilation #PharmaFlow
102 News #PharmaBuzz

ACTIVE PHARMA INGREDIENTS

85 All APIs, 24 USDMF, 40 CEP/COS, 38 JDMF, 27 NDC API, 3 VMF, 29 Listed APIs

85 All APIs
24 USDMF
40 CEP/COS
38 JDMF
27 NDC API
3 VMF
29 Listed APIs

DEVELOPMENTS

1 Drugs in Development

1 Drugs in Development

INSPECTIONS & REGISTRATIONS

113 FDA, 21 EDQM, 3 GDUFA

inspections
113 FDA
21 EDQM
3 GDUFA

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Royal DSM, founded in 1902, is a global, purpose-led health, nutrition, and bioscience company that specializes in human and animal health and nutrition solutions. Its primary goal is to develop health and nutrition solutions that are scientifically sound. Royal DSM's products and solutions address some of the world's most pressing issues while also adding economic, environmental and societal value to all stakeholders. More than 2.5 billion people worldwide use the company's solutions. Royal DSM and its affiliated companies employ approximately 23,000 people worldwide and generate around €10 billion in net sales per year.

CPhI ChinaCPhI China

Not Confirmed

Not Confirmed

24-26 June, 2025

SNIEC, Shanghai, China
India Med ExpoIndia Med Expo

Not Confirmed

Not Confirmed

23-25 May, 2025

Greater Noida, Delhi
PharmaVenuePharmaVenue

Not Confirmed

Not Confirmed

26-27 May, 2025

Madrid

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown

Country

Netherlands

Address

Het Overloon 1, 6411 TE Heerlen

Telephone

+31 45 578 8111

enquiries@pharmacompass.com

Website

https://www.dsm.com/corporate/home.html

https://www.linkedin.com/company/dsm/

YouTube

Digital content

Create Content with PharmaCompass, ask us

INTERVIEW #SpeakPharma

[Sponsored by another company]

Alchem NicSelect™ grants customers royalty-free access to T-MAX™ tech for 3-in-1 vape satisfaction in flavour-restricted markets

With increasing flavour bans in key markets, vaping brands are facing significant challenges in providing satisfying alternatives to vapers and smokers looking to transition. Recognising this need, Alchem NicSelect™ is making a bold move by offering its key customers royalty-free and unrestricted geographical access to its revolutionary T-MAX™ technology.“At Alchem NicSelect™, we understand the urgency for vaping brands to adapt to new regulations without compromising on satisfaction. By offering royalty-free access to T-MAX™ technology, we empower our customers to provide the closest cigarette-like experience possible, even in markets with strict flavour restrictions,” said Riccardo Santambrogio, Europe Sales Manager.HIGHLIGHTS// offering royalty-free access to T-MAX™ technology/ unrestricted geographical access/ closest cigarette-like experience Addressing the biggest barrier: Nicotine satisfactionOne of the primary reasons many vapers are dissatisfied and smokers struggle to switch to vaping is that traditional nicotine solutions fail to replicate the rapid satisfaction provided by cigarettes. Nicotine replacement therapies (NRTs) and even conventional vaping products often lack the immediate nicotine hit, throat feel, and overall experience that smokers are accustomed to. T-MAX™ solves this problem by engineering a nicotine experience that closely mimics cigarette consumption without relying on flavours.T-MAX™ provides a unique 3-in-1 approach:1. The Speed of a Cigarette – Rapid nicotine delivery and rush within seconds for immediate satisfaction.2. The Power of Nicotine Salts – A stronger perceived nicotine effect without exceeding legal limits (20 mg/ml nicotine limit under the European Tobacco Products Directive). With T-MAX™, 8 mg/ml feels like 20 mg/ml, and 14 mg/ml feels like 40 mg/ml.3. The Throat Hit of Freebase Nicotine – Especially in a flavour-free formulation, the combined ingredients in T-MAX™ deliver an even more satisfying throat feel than expected from nicotine base, much closer to and more familiar with a cigarette throat feel that habitual smokers recognise.HIGHLIGHTS// unique 3-in-1 approach/ rush within seconds/ stronger perceived nicotine effect without exceeding legal limits/ more satisfying throat feel that habitual smokers recogniseNo flavour, but not less satisfyingWhile flavours have traditionally played a role in vaping adoption, market realities are shifting. With flavour bans spreading across regions, brands need solutions that deliver satisfaction without relying on taste. Consumer research has shown that T-MAX™ performs exceptionally well even without added flavours. Since most cigarette smokers do not smoke for the tobacco flavour but rather for the nicotine hit and habitual experience, T-MAX™ provides a viable alternative that aligns with new regulatory landscapes.HIGHLIGHTS// flavour bans spreading across regions/ T-MAX™ performs exceptionally well even without added flavoursEmpowering vape brands with free access to T-MAX™By granting customers royalty-free access to the T-MAX™ technology, Alchem NicSelect™ is removing barriers for vaping brands and original equipment manufacturers (OEMs) looking to adapt to regulatory changes. This open-access approach ensures that manufacturers can integrate T-MAX™ into their product lines without additional costs, allowing them to offer superior nicotine satisfaction in markets where flavours are no longer an option.HIGHLIGHTS// removing barriers for vaping brands and OEMs looking to adapt/ manufacturers can integrate T-MAX™ into product lines without additional costsThe future of vaping in restricted marketsWith T-MAX™, the vaping industry has a powerful tool to retain customers and convert smokers who have struggled with traditional vaping products. By delivering the key elements of cigarette satisfaction — without combustion or flavours — T-MAX™ is set to redefine what a satisfying vape experience means in a post-flavour-ban world.“Our commitment to innovation and accessibility means we are providing our customers with the solutions they need to navigate an evolving regulatory landscape. T-MAX™ allows brands to offer a highly satisfying experience that mimics smoking without relying on flavours. The message is clear: no flavour, but not less satisfying”, added Santambrogio.HIGHLIGHTS// powerful tool to retain customers and convert smokers/ delivering the key elements of cigarette satisfaction without combustion or flavours/ no flavour, but not less satisfying

Impressions: 569

VLOG #PharmaReel

[Sponsored by another company]

Connecting People, Mentalities & Markets

This PharmaReel highlights Transo-Pharm USA’s offerings of premium Phyto Cannabidiol (CBD) and Phyto Cannabigerol (CBG) isolates from its cGMP-certified facility inspected by the FDA and ANVISA. The company has an expanded reach across the US and EU.

Impressions: 656

DATA COMPILATION #PharmaFlow

[Sponsored by another company]

US drug shortages reduce 16% YoY in Q1 2025; CNS drugs, antimicrobials face highest scarcities

The pharmaceutical industry in the United States continued to grapple with drug shortages during the first quarter (Q1) of 2025. According to the American Society of Health‑System Pharmacists (ASHP), the total number of active shortages stood at 270 as of March 31, 2025 — only slightly below the 277 reported in September 2024, but down 16.4 percent from an all‑time high of 323 reported in Q1 2024.These numbers imply that while dramatic surges in drug shortages may have subsided, underlying vulnerabilities in manufacturing, supply chains, and raw‑material sourcing continue to frustrate efforts towards a durable resolution.A deeper analysis of these drug scarcities reveals that 41 percent of the 270 active shortages first emerged in 2022 or earlier. This implies that many of the current disruptions have become chronic in nature and are exerting pressure on pharmacy operations. View Our Interactive Dashboard on Drug Shortages So Far in 2025 (Free Excel Available)CNS drugs dominate with 49 meds in short supply; antimicrobials face shortage of 39 drugsClass‑specific analysis reveals that central nervous system (CNS) agents remained the most disrupted category, with 49 distinct CNS drugs having faced scarcities during Q1. This group spans anxiolytics (anti-anxiety drugs) such as clonazepam and flurazepam, sedatives like lorazepam and midazolam, and stimulants such as methylphenidate and lisdexamfetamine. These shortages pose two challenges — controlling seizures and managing sedation in acute care settings. After CNS agents, antimicrobials was the second‑largest category, with shortages affecting 39 drugs. Key antibacterial and anti-fungal agents such as cefotaxime sodium powder for injection, clindamycin phosphate, rifampin, and metronidazole find themselves on ASHP’s active‑shortage roster, threatening both routine hospital protocols and emergency sepsis management.Fluids and electrolytes occupied the third spot, with 29 items facing shortage in Q1 2025. Hormone agents, including insulin analogs, ranked fourth with 24 drugs in short supply.Chemotherapy medications rounded out the top five categories, with 23 antineoplastic agents (a broad class of medications used to treat cancer) flagged as actively constrained in Q1 2025. Notable shortages included azacitidine, carboplatin, methotrexate, and streptozocin. View Our Interactive Dashboard on Drug Shortages So Far in 2025 (Free Excel Available) US faces 26 new shortages; Pharmacopeia list warns of 100 vulnerable medicationsThe first quarter saw the emergence of 26 new shortage declarations, emphasizing that even drugs previously deemed reliably sourced can fall into scarcity. The US has been facing a shortage of attention deficit hyperactivity disorder (ADHD) drugs since 2022. The new shortages included ADHD transdermal patch methylphenidate, peginterferon alfa‑2a (Pegasys) used in chronic hepatitis B and C, and bacitracin ophthalmic ointment.The fragility of the pharmaceutical supply chains has been particularly evident in the aftermath of natural disasters. Hurricane Helene’s flooding at Baxter’s Marion, North Carolina, facility deeply affected IV‑solution supply lines. Baxter supplies roughly 60 percent of the US’ IV fluids and the ASHP report listed “hurricane” as the reason behind nine percent of drug shortages, as of January 2025.Regulatory and policy interventions continue to evolve. The US Pharmacopeia’s inaugural Vulnerable Medicines List, launched in 2025, identifies 100 drugs at the highest risk of future shortages, with a particular focus on injectables (comprising 71 percent of the list) and essential hospital care.Antibiotics, medications for pain management and oncology are the other drugs on the list. Although 61 percent of these vulnerable medicines were not in active shortage at the time of listing, their inclusion is intended to galvanize manufacturers and purchasing organizations to bolster inventories.Meanwhile, the Government Accountability Office in the US has called on the Department of Health and Human Services (HHS) to establish a formal coordination mechanism, warning that elimination of the HHS supply‑chain coordinator role in May 2025 risks fragmenting federal response efforts. View Our Interactive Dashboard on Drug Shortages So Far in 2025 (Free Excel Available) Global shortages mirror US patterns; Europe launches monitoring platform Globally, we notice comparable trends. For instance, Europe has rolled out the European Shortages Monitoring Platform (ESMP) this year in order to centralize shortage reporting across member states. Critical‑medicine shortages in the EU — in areas such as oncology, ADHD, and critical care analgesics — mirror US patterns. The European Medicines Agency’s shortage list currently holds 37 human drugs.According to Health Canada’s May 12, 2025 update, its Tier 3 list had 18 drug shortages that are considered to have the greatest impact on Canada’s drug supply and health‑care system. Tier 3 designation is based on medical necessity and minimal availability of alternatives.In hematology and oncology, scarcity of essential drugs like Oncaspar for acute lymphoblastic leukemia, idarubicin and lomustine for leukemias and brain tumors, anagrelide for thrombocythemia, and preservative‑free methotrexate for various malignancies underscore the impact these drug shortages can have on treatment. View Our Interactive Dashboard on Drug Shortages So Far in 2025 (Free Excel Available) Our viewThe global pharma supply chain is dealing with a fresh wave of uncertainties, especially with the likelihood of tariffs on drugs imported into the US. Analysts warn that the proposed pharmaceutical tariffs could exacerbate supply issues.Over 50 percent of drugs used in the US are manufactured abroad. Generic sterile injectable drugs — like chemotherapy medications and IV saline — are particularly vulnerable due to their complex manufacturing processes and low profit margins. Generic drugs (which account for 90 percent of prescriptions filled in the US) could face increased pressure, as many rely on raw materials from China and India. This could result in more severe drug shortages in the future.

Impressions: 433

NEWS #PharmaBuzz

Basilea Posts Strong 2024 Results With Higher Revenue, Profit

18 Feb 2025

// GLOBENEWSWIRE

dsm-firmenich launches food and beverages pilot plant in US

21 Mar 2024

// INDINPHARMAPOST

DSM provides Q1 2023 trading update

02 May 2023

// PRESS RELEASE

DSM Acquires Adare Biome for €275 million

21 Apr 2023

// CONTRACT PHARMA

DSM completes sale of Engineering Materials business

03 Apr 2023

// PRESS RELEASE

DSM reports 2022 results

16 Feb 2023

// PRESS RELEASE

ALL APIs

Click the button for full data set

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

01

5% D-methorphan Hydrobromide Adsorba...

Netherlands

India Med Expo

Not Confirmed

Not Confirmed

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

CEP/COS

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

JDMF

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

Only 10 entries up to this point, click to access all

VMF

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

LISTED APIs

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Inspections and registrations

Upload your audits for free, ask us

FDA

01 FDA Audited

USA

USA

India Med Expo

Not Confirmed

10 FDA Audited

USA

India Med Expo

Not Confirmed

India Med Expo

Not Confirmed

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

GDUFA

01 GDUFA fees paid

USA

India Med Expo

Not Confirmed

02 GDUFA fees paid

USA

India Med Expo

Not Confirmed

03 GDUFA fees paid

USA

India Med Expo

Not Confirmed

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Contact Fersinsa Gb, S.A. de C.V. and get a quotation

Fersinsa Gb, S.A. de C.V. is a supplier offers 70 products (APIs, Excipients or Intermediates).

Find a price of Ascorbic Acid bulk with DMF, CEP, JDMF offered by Fersinsa Gb, S.A. de C.V.

Find a price of Biotin bulk with DMF, CEP, JDMF offered by Fersinsa Gb, S.A. de C.V.

Find a price of D-Panthenol bulk with DMF, CEP, JDMF offered by Fersinsa Gb, S.A. de C.V.

Find a price of Folic Acid bulk with DMF, CEP, JDMF offered by Fersinsa Gb, S.A. de C.V.

Find a price of Pyridoxine Hydrochloride bulk with DMF, CEP, JDMF offered by Fersinsa Gb, S.A. de C.V.

Find a price of Riboflavin 5 Phosphate Sodium bulk with DMF, CEP, JDMF offered by Fersinsa Gb, S.A. de C.V.

Find a price of Thiamine Hydrochloride bulk with DMF, CEP, JDMF offered by Fersinsa Gb, S.A. de C.V.

Find a price of Vitamin D3 bulk with DMF, CEP, JDMF offered by Fersinsa Gb, S.A. de C.V.

Find a price of Vitamin E Acetate bulk with DMF, CEP, JDMF offered by Fersinsa Gb, S.A. de C.V.

Find a price of Vitamin K1 bulk with DMF, CEP, JDMF offered by Fersinsa Gb, S.A. de C.V.

Find a price of Amoxicillin Trihydrate bulk with DMF, CEP offered by Fersinsa Gb, S.A. de C.V.

Find a price of Ampicillin bulk with DMF, CEP offered by Fersinsa Gb, S.A. de C.V.

Find a price of Ampicillin Trihydrate bulk with DMF, CEP offered by Fersinsa Gb, S.A. de C.V.

Find a price of Benzylpenicillin Sodium bulk with CEP, JDMF offered by Fersinsa Gb, S.A. de C.V.

Find a price of Fluocytosine bulk with CEP, JDMF offered by Fersinsa Gb, S.A. de C.V.

Find a price of Pyridoxine Hydrochloride bulk with CEP, JDMF offered by Fersinsa Gb, S.A. de C.V.

Find a price of Riboflavin bulk with CEP, JDMF offered by Fersinsa Gb, S.A. de C.V.

Find a price of Sodium Ascorbate bulk with DMF, CEP offered by Fersinsa Gb, S.A. de C.V.

Find a price of Thiamine Mononitrate bulk with CEP, JDMF offered by Fersinsa Gb, S.A. de C.V.

Find a price of Vitamin A bulk with CEP, JDMF offered by Fersinsa Gb, S.A. de C.V.

Find a price of Vitamin A Acetate bulk with CEP, JDMF offered by Fersinsa Gb, S.A. de C.V.

Find a price of Vitamin A Palmitate bulk with DMF, JDMF offered by Fersinsa Gb, S.A. de C.V.

Find a price of Vitamin D3 bulk with DMF, CEP offered by Fersinsa Gb, S.A. de C.V.

Find a price of Vitamin E bulk with CEP, JDMF offered by Fersinsa Gb, S.A. de C.V.

Find a price of Vitamin E Acetate bulk with CEP, JDMF offered by Fersinsa Gb, S.A. de C.V.

Find a price of Aprotinin bulk with JDMF offered by Fersinsa Gb, S.A. de C.V.

Find a price of Ascorbic Acid bulk with JDMF offered by Fersinsa Gb, S.A. de C.V.

Find a price of Ascorbyl Palmitate bulk with CEP offered by Fersinsa Gb, S.A. de C.V.

Find a price of Beta Carotene bulk with CEP offered by Fersinsa Gb, S.A. de C.V.

Find a price of Calcium Ascorbate bulk with CEP offered by Fersinsa Gb, S.A. de C.V.

Find a price of Calcium Pantothenate bulk with JDMF offered by Fersinsa Gb, S.A. de C.V.

Find a price of Colesevelam Hydrochloride bulk with DMF offered by Fersinsa Gb, S.A. de C.V.

Find a price of Collagen bulk with CEP offered by Fersinsa Gb, S.A. de C.V.

Find a price of Dextromethorphan Hydrobromide bulk with DMF offered by Fersinsa Gb, S.A. de C.V.

Find a price of Neostigmine Methylsulfate bulk with DMF offered by Fersinsa Gb, S.A. de C.V.

Find a price of Pantothenic Acid bulk with CEP offered by Fersinsa Gb, S.A. de C.V.

Find a price of Penicillin G Potassium bulk with DMF offered by Fersinsa Gb, S.A. de C.V.

Find a price of Pyridostigmine bulk with DMF offered by Fersinsa Gb, S.A. de C.V.

Find a price of Silver Sulfadiazine bulk with DMF offered by Fersinsa Gb, S.A. de C.V.

Find a price of Thiamine Hydrochloride bulk with JDMF offered by Fersinsa Gb, S.A. de C.V.

Find a price of Thiamine Mononitrate bulk with JDMF offered by Fersinsa Gb, S.A. de C.V.

Find a price of Vitamin A bulk with JDMF offered by Fersinsa Gb, S.A. de C.V.

Find a price of Vitamin A Acetate bulk with JDMF offered by Fersinsa Gb, S.A. de C.V.

Find a price of Vitamin A Palmitate bulk with JDMF offered by Fersinsa Gb, S.A. de C.V.

Find a price of Vitamin D3 bulk with CEP offered by Fersinsa Gb, S.A. de C.V.

Find a price of Vitamin E bulk with JDMF offered by Fersinsa Gb, S.A. de C.V.

Find a price of Hemokoaguraze solution bulk with JDMF offered by Fersinsa Gb, S.A. de C.V.

Find a price of Amoxicillin Trihydrate bulk offered by Fersinsa Gb, S.A. de C.V.

Find a price of Vitamin D3 bulk offered by Fersinsa Gb, S.A. de C.V.

Find a price of Vitamin E Acetate bulk offered by Fersinsa Gb, S.A. de C.V.

Find a price of Arachidonic Acid bulk offered by Fersinsa Gb, S.A. de C.V.

Find a price of Avobenzona bulk offered by Fersinsa Gb, S.A. de C.V.

Find a price of Benzyl Penicillin bulk offered by Fersinsa Gb, S.A. de C.V.

Find a price of Biotin bulk offered by Fersinsa Gb, S.A. de C.V.

Find a price of Cannabidiol bulk offered by Fersinsa Gb, S.A. de C.V.

Find a price of DHA bulk offered by Fersinsa Gb, S.A. de C.V.

Find a price of Dimethicone bulk offered by Fersinsa Gb, S.A. de C.V.

Find a price of Ensulizole bulk offered by Fersinsa Gb, S.A. de C.V.

Find a price of Folic Acid bulk offered by Fersinsa Gb, S.A. de C.V.

Find a price of Icosapent Ethyl bulk offered by Fersinsa Gb, S.A. de C.V.

Find a price of Niacin bulk offered by Fersinsa Gb, S.A. de C.V.

Find a price of Nicotinamide bulk offered by Fersinsa Gb, S.A. de C.V.

Find a price of Nystatin bulk offered by Fersinsa Gb, S.A. de C.V.

Find a price of Penicillin G Procaine bulk offered by Fersinsa Gb, S.A. de C.V.

Find a price of Sodium Ascorbate bulk offered by Fersinsa Gb, S.A. de C.V.

Find a price of Tiamulin Fumarate bulk offered by Fersinsa Gb, S.A. de C.V.

Find a price of Vitamin B1 bulk offered by Fersinsa Gb, S.A. de C.V.

Find a price of Vitamin B12 bulk offered by Fersinsa Gb, S.A. de C.V.

Find a price of Vitamin D bulk offered by Fersinsa Gb, S.A. de C.V.

Find a price of Zinc Oxide bulk offered by Fersinsa Gb, S.A. de C.V.

Company profile for Royal DSM

VISIT THE VIRTUAL BOOTH

Review portfolio & marketing content

CONTACT DETAILS

Google Map, LinkedIn, Emails...

EVENTS

Webinars & Exhibitions

DIGITAL CONTENT

Interview #SpeakPharma

Vlog #PharmaReel

Data Compilation #PharmaFlow

102 News #PharmaBuzz

ACTIVE PHARMA INGREDIENTS

85 All APIs

24 USDMF

40 CEP/COS

38 JDMF

27 NDC API

3 VMF

29 Listed APIs

DEVELOPMENTS

1 Drugs in Development

INSPECTIONS & REGISTRATIONS

113 FDA

21 EDQM

3 GDUFA

01

02

03

04

05

06

07

08

09

10

01

FDA Audited

FDA Audited

02

FDA Audited

FDA Audited

03

FDA Audited

FDA Audited

04

FDA Audited

FDA Audited

05

FDA Audited

FDA Audited

06

FDA Audited

FDA Audited

07

FDA Audited

FDA Audited

08

FDA Audited

FDA Audited

09

FDA Audited

FDA Audited

10

FDA Audited

FDA Audited

01

GMP Certified

GMP Certified

02

GMP Certified

GMP Certified

03

GMP Certified

GMP Certified

04

GMP Certified

GMP Certified

05

GMP Certified